2024
TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial
Al Malki M, Keyzner A, Popat U, Chen Y, Suh H, Jain T, Solh M, Snow A, Gill S, Gowda L, Uberti J, Buonomo E, Wang Y, Nabilsi N, White T, Nguyen C, Murray J, MacBeath G, Louis C, Chattopadhyay S, Matzko M, Reshef R. TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial. Blood 2024, 144: 924. DOI: 10.1182/blood-2024-201526.Peer-Reviewed Original ResearchReduced intensity conditioningRelapse-free survivalPost-HCTDonor chimerismTreatment armsFollow-upControl armMalignant lineagesGrade 2-4 acute graft-versus-host diseaseT cell receptor-engineered T cellsControl subjectsIncreased relapse-free survivalGraft-versus-host diseaseMedian time to relapseControl arm subjectsNon-relapse deathPost-HCT MRDComplete donor chimerismDonor-derived cellsEngineered T cellsMedian follow-upTime to relapseCD3+ cellsPhase 1 studyARMS subjects
2021
Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation–A Systematic Review and Meta-Analysis
Bewersdorf JP, Allen C, Mirza AS, Grimshaw AA, Giri S, Podoltsev NA, Gowda L, Cho C, Tallman MS, Zeidan AM, Stahl M. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation–A Systematic Review and Meta-Analysis. Transplantation And Cellular Therapy 2021, 27: 997.e1-997.e11. PMID: 34551341, PMCID: PMC9533376, DOI: 10.1016/j.jtct.2021.09.005.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaRelapse-free survivalMaintenance therapyMyelodysplastic syndromeFLT3 inhibitorsAllo-HCTHazard ratioMaintenance treatmentClinical trialsMyeloid leukemiaAllogeneic hematopoietic stem cell transplantationControl groupSystematic reviewAllogeneic hematopoietic cell transplantMeasurable residual disease statusHematopoietic stem cell transplantationMeasurable residual disease testingNon-relapse mortalityHematopoietic cell transplantPre-emptive treatmentResidual disease statusStem cell transplantationFavorable safety profileSame patient cohortRandom-effects model
2020
Predictive Value of PET-CT in Patients with T-Cell Lymphoma Undergoing Autologous and Allogeneic Stem Cell Transplant
Isufi I, Chandhok N, Boddu P, Pucar D, Seropian S, Gowda L, Perreault S, Wilson L, Roberts K, Foss F. Predictive Value of PET-CT in Patients with T-Cell Lymphoma Undergoing Autologous and Allogeneic Stem Cell Transplant. Transplantation And Cellular Therapy 2020, 26: s244. DOI: 10.1016/j.bbmt.2019.12.492.Peer-Reviewed Original ResearchRelapse-free survivalPET-CT scanTime of SCTTime of alloSCTPET-CTT-NHLBM biopsyAllo-SCTCT scanPositive PET/CT scanPredictive valueLong-term relapse-free survivalPositive PET-CT scanAllogeneic stem cell transplantPeripheral blood flow cytometryPET/CT scansIntermediate-high riskBlood flow cytometryAggressive clinical courseStem cell transplantT-cell lymphomaMajority of ptsPositive PET-CTAuto-SCTMedian follow